If you have been reading about gastric juice and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-12. Numbers and descriptions here follow the published literature rather than marketing material.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
Some enzymes need to go through a maturation process to be activated. A precursor (inactive state, better known as zymogen) is first synthesized, and then, by cutting some specific peptide bonds (enzymatic catalysis by hydrolytic selective split), its 3D conformation is highly modified into a catalytic functional status, obtaining the active enzyme. Proteolysis is irreversible and normally a non-specific process. The same activator can modulate different regulatory enzymes : once trypsin is activated, it activates many other hydrolytic enzymes. Proteolysis can also be fast and simple so the hydrolysis of a single peptide bond can be enough to change the conformation of the protein and build an active zone, allowing the interaction between the enzyme and the substrate, for instance, chymotrypsin activation (as it can be seen in the images). Many different types of proteins with different roles in metabolism are activated by proteolysis for big reasons:
== List of women chemists == The following list is split into the centuries when the majority of the scientist's work was performed. The scientist's listed may be born and perform work outside of the century they are listed under.
A lectin from Dolichos biflorus is used to identify cells that belong to the A1 blood group. A lectin from Ulex europaeus is used to identify the H blood group antigen. A lectin from Vicia graminea is used to identify the N blood group antigen. A lectin from Iberis amara is used to identify the M blood group antigen. In neuroscience, the anterograde labeling method is used to trace the path of efferent axons with PHA-L, a lectin from the kidney bean. A lectin (BanLec) from bananas inhibits HIV-1 in vitro. Achylectins, isolated from Tachypleus tridentatus, show specific agglutinating activity against human A-type erythrocytes. Anti-B agglutinins such as anti-BCJ and anti-BLD separated from Charybdis japonica and Lymantria dispar, respectively, are of value both in routine blood grouping and research. The fucose-binding lectin LecB of Pseudomonas aeruginosa, which contributes to bacterial adhesion and biofilm formation, has been investigated as a molecular target using photoswitchable glycomimetic ligands. One such ligand, photofucose-2, showed different binding affinities for LecB in its cis and trans forms, and the protein–ligand complex was characterized by X-ray crystallography.
Carbohydrate consumed in food yields 3.87 kilocalories of energy per gram for simple sugars, and 3.57 to 4.12 kilocalories per gram for complex carbohydrate in most other foods. Relatively high levels of carbohydrate are associated with processed foods or refined foods made from plants, including sweets, cookies and candy, table sugar, honey, soft drinks, breads and crackers, jams and fruit products, pastas and breakfast cereals. Refined carbohydrates from processed foods such as white bread or rice, soft drinks, and desserts are readily digestible, and many are known to have a high glycemic index, which reflects a rapid assimilation of glucose. By contrast, the digestion of whole, unprocessed, fiber-rich foods such as beans, peas, and whole grains produces a slower and steadier release of glucose and energy into the body. Animal-based foods generally have the lowest carbohydrate levels, although milk does contain a high proportion of lactose. Organisms typically cannot metabolize all types of carbohydrate to yield energy. Glucose is a nearly universal and accessible source of energy. Many organisms also have the ability to metabolize other monosaccharides and disaccharides but glucose is often metabolized first. In Escherichia coli, for example, the lac operon will express enzymes for the digestion of lactose when it is present, but if both lactose and glucose are present, the lac operon is repressed, resulting in the glucose being used first (see: Diauxie). Polysaccharides are also common sources of energy.
=== Ratings === Streaming analytics firm FlixPatrol, which monitors daily updated VOD charts and streaming ratings worldwide, reported that following the season's premiere American Horror Story topped the streaming chart on Hulu among all programs and on Disney+ among the series. Internationally, it ranked among the top titles on Disney+ in multiple countries, while in Australia it was the most-streamed series on Binge.
Sources: en.wikipedia.org
==== The tandem principle ==== The solution emerged from a charge-reversal concept proposed demonstrated by Nobel laureate Luis Alvarez in 1951. Rather than accelerate positive ions from ground to a high-voltage terminal, the tandem accelerator begins with negative ions. These particles accelerate toward a positive terminal, where a thin foil or gas stripper removes multiple electrons, converting them to positive ions. The now-positive particles accelerate away from the terminal back to ground potential. This double acceleration effectively multiplies the particle energy without requiring proportionally higher terminal voltages. A negative hydrogen ion accelerated through a 5 megavolt tandem emerges with 10 megavolts of kinetic energy. After commissioning tandem production in 1954, Atomic Energy of Canada Limited placed HVEC's first tandem order in September 1956 for $0.92M (equivalent to $10.89M in 2025). The machine achieved first beam at HVEC's Burlington facility in June 1958.
== Performance measures == The South African logistics sector ranks highly on a global scale, and rankings are continuing to increase. According to indices from the World Bank, as of 2026, SA's logistics infrastructure and performance are comparable to those of China and the United States. South Africa ranked joint 19th place, out of 139 countries in the 2023 World Bank Logistics Performance Index - an increase of 14 places year-over-year. There are various measures of performance for South African logistics, with a mix of indices, ranks, and other metrics from the a national and node-specific perspective. According to the Council for Scientific and Industrial Research, some of these are:
=== Kristina Braverman === Kristina Anna Nichols Braverman (Monica Potter) is Adam's wife, and a source of stability and support for anyone who needs it. She is portrayed as a typical soccer mom who works to keep her family happy. Official material from NBC characterises her as a "wise and quietly forceful woman who loves her husband and children deeply and with incredible strength." While she is always caring and nurturing, she can be high-strung and worried at times, perhaps as a result of raising a son with Asperger's syndrome. In season two, when Haddie moves in with Adam's parents for a few weeks, it is revealed that Kristina's parents ran away and married one another when they were 16. She mentions that her father made her mother miserable for her entire life. Although it has not been explored, it has been strongly hinted that Kristina's home life while growing up was far from ideal and she has expressed to Camille that she (Camille) was a substitute mother for her. She goes back to work to support her family during her husband's unemployment, then quits, but goes back to work after Adam tells her that Rachel, his assistant at the recording studio, kissed him. She forgives him for this transgression, despite Adam's refusal to fire Rachel. Kristina initially disapproved of her daughter's relationship with her recovering alcoholic boyfriend, but eventually came around. In the fourth season premiere, she was diagnosed with breast cancer and faced many hardships as a result, despite overwhelming support from her family.
=== Normal, prediabetic, and diabetic ranges === The 2010 American Diabetes Association Standards of Medical Care in Diabetes added the HbA1c ≥ 48 mmol/mol (≥6.5 DCCT %) as another criterion for the diagnosis of diabetes.
==== Charge site-initiated cleavage ==== The driving force of charge site-initiated fragmentation is the inductive effect of the charge site in radical cations. The electrons from the bond adjacent to the charge-bearing atom migrate to that atom, neutralizing the original charge and causing it to move to a different site. This term is also called inductive cleavage and is an example of heterolytic bond cleavage.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.